The country's Intellectual Property Institute has now issued an Instruction on the Granting of Compulsory Licences for Patented Drugs, in accordance with local IP legislation and is open to receive applications for the grant of compulsory licences, whether for commercial or non-commercial public use. It is for the applicant to show that the product or medicine which it will produce or import is primarily intended for supply within the domestic market. In the case of
"Article 32 of the Constitution, which establishes that health is a right guaranteed by the state;
Article 31 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which recognizes the right of countries to grant compulsory licences for patented medicines in order to combat and mitigate the effects of illnesses;
and the Doha Declaration regarding the TRIPS Agreement and public health, which states that each World Trade Organization member state "has the right to grant compulsory licences and the freedom to determine the bases upon which such licences may be granted".
an application for commercial public use, the applicant must show that it tried to obtain authorization from the rights holder on "commercially reasonable terms and conditions" and that a favourable response was not obtained within a period of 45 days.
For further details, please refer to the article.